Compugen (NASDAQ:CGEN) Hits 52-week High

Subscribe to daily free stock newsletter on top stocks by visiting :  http://www.pennystockpickreport.com/

Shares of Compugen Ltd. (USA) (NASDAQ:CGEN) soared 33% to $5.42 after hitting a 52-week high of $5.86 earlier.

Today, Compugen Ltd. announced the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors. CGEN-671 is a membrane splice variant of CD55, a known drug target for gastric cancer for which monoclonal antibody (mAb) therapeutics are in clinical development by others. The potential application of CGEN-671 as a drug target was initially predicted in silico by Compugen through the use of its Monoclonal Antibody Targets Discovery Platform; the predicted molecule was then validated experimentally in multiple epithelial tumors.

About http://www.pennystockpickreport.com/

Penny Stock Pick Report offers a stock newsletter on OTC, PINKSHEETS ,OTCBB, and AMEX Stocks. Our subscribers receive daily up to date stock information on midcap,smallcap penny stocks and also stocks that are traded at NASDAQ and NYSE stock exchange. If you wish to feature your organization on our website then you can contact us at the email given below.